{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:19Z","timestamp":1793157439924,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM19\/00087"],"award-info":[{"award-number":["CM19\/00087"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100090","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:55:58Z","timestamp":1616086558000},"page":"100090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study"],"prefix":"10.1016","volume":"6","author":[{"given":"J.","family":"Ruiz-Ba\u00f1obre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molina-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fern\u00e1ndez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fern\u00e1ndez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Medina-Colmenero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Santom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mateos-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Garc\u00eda-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Anido-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2021.100090_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100090_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100090_bib3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100090_bib4","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100090_bib5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100090_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","article-title":"Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials","volume":"63","author":"Sonpavde","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100090_bib7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/1097-0142(19910315)67:6<1525::AID-CNCR2820670611>3.0.CO;2-8","article-title":"Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy","volume":"67","author":"Geller","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.urology.2006.12.010","article-title":"Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens","volume":"69","author":"Lin","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.esmoop.2021.100090_bib9","doi-asserted-by":"crossref","first-page":"v118","DOI":"10.1093\/annonc\/mdj965","article-title":"Long-term survival results of a randomized trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer","volume":"17","author":"Roberts","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100090_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.10762","article-title":"Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I\/II trial with paclitaxel, cisplatin, and gemcitabine","volume":"95","author":"Bellmunt","year":"2002","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100090_bib11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100090_bib12","first-page":"1173","article-title":"Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors","volume":"204","author":"Sonpavde","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100090_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"Eur Urol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2021.100090_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2018.36.6_suppl.426","article-title":"Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma","volume":"36","author":"Necchi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100090_bib15","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2021.100090_bib17","doi-asserted-by":"crossref","first-page":"x40","DOI":"10.1093\/annonc\/mdy511.001","article-title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","volume":"29","author":"Homicsko","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100090_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"issue":"10031","key":"10.1016\/j.esmoop.2021.100090_bib19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100090_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100090_bib21","doi-asserted-by":"crossref","first-page":"12000","DOI":"10.1200\/JCO.2018.36.15_suppl.12000","article-title":"Association of high tissue TMB and atezolizumab efficacy across multiple tumor types","volume":"36","author":"Legrand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100090_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41416-019-0686-0","article-title":"A\u00a0model combining clinical and genomic factors to predict response to PD-1\/PD-L1 blockade in advanced urothelial carcinoma","volume":"122","author":"Nassar","year":"2020","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.esmoop.2021.100090_bib23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100090_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100090_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100090_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100090_bib27","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100090_bib28","doi-asserted-by":"crossref","first-page":"e1002309","DOI":"10.1371\/journal.pmed.1002309","article-title":"Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis","volume":"14","author":"Snyder","year":"2017","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100090_bib29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","volume":"29","author":"Penault-Llorca","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100090_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4615-1941-6_15","article-title":"Assessment of engraftment and function of human tonsillar and blood mononuclear cells in immunodeficient mice","volume":"371A","author":"Albini","year":"1995","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11523-018-0561-6","article-title":"Atezolizumab in metastatic urothelial carcinoma outside clinical trials: focus on efficacy, safety, and response to subsequent therapies","volume":"13","author":"Barata","year":"2018","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100090_bib32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2018.02.010","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: clinical experience from an expanded access study in the United States","volume":"73","author":"Pal","year":"2018","journal-title":"Eur Urol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2021.100090_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.2019.37.7_suppl.381","article-title":"Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving atezolizumab (atezo) monotherapy in United States clinical practice","volume":"37","author":"Mhatre","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib34","first-page":"709","article-title":"Comparative effectiveness of immune checkpoint inhibitors in patients with platinum-refractory advanced urothelial carcinoma","volume":"205","author":"Umang","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1515\/pp-2016-0015","article-title":"Functional vascular anatomy of the peritoneum in health and disease","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100090_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis"},{"issue":"5706","key":"10.1016\/j.esmoop.2021.100090_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100090_bib38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1245\/s10434-020-08591-7","article-title":"Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer","volume":"28","author":"Miller","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib39","first-page":"852","article-title":"Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread","volume":"187","author":"Rafael","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100090_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100090_bib41","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/1078155218771152","article-title":"Do proton pump inhibitors modulate the efficacy of anti-PD-1\/PD-L1 therapy? A retrospective study","volume":"25","author":"Mukherjee","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2021.100090_bib42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2020.38.6_suppl.500","article-title":"Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC)","volume":"38","author":"Morales-Barrera","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100090_bib43","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2018.11.071","article-title":"DNA mismatch repair deficiency and immune checkpoint inhibitors in gastrointestinal cancers","volume":"156","author":"Ruiz-Ba\u00f1obre","year":"2019","journal-title":"Gastroenterology"},{"issue":"6264","key":"10.1016\/j.esmoop.2021.100090_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.esmoop.2021.100090_bib45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.esmoop.2021.100090_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.esmoop.2021.100090_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100090_bib48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100090_bib49","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100090_bib50","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"J\u00a0Am Med Assoc"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:00Z","timestamp":1761855900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2059702921000478"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100090","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100090"}}